e-Drug3D

1948

TAZEMETOSTAT

INN
TAZEMETOSTAT

cas 1403254-99-8

CLASS

ANTINEOPLASTIC
METHYLTRANSFERASE INHIBITOR
TREATMENT OF METASTATIC OR LOCAL ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION

ROUTE (list)

ORAL

ATC code

L01XX72

PK parameters

F 33 PERCENT
Tmax 1.5 HOUR
VD 1230 LITER
Cl 274 LITER / HOUR
PPB 88 PERCENT
t1/2 3.1 HOUR

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET METHYLTRANSFERASE EZH2

DrugCentral

Histone-lysine N-methyltransferase EZH2 UNIPROT Q15910 EZH2

Download SDF file

[1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-

Formula:
C34H44N4O4

Calculated chemical properties:

MW 572.73
NB_atoms 42
XLogP 4.73
PSA 86.045
NB_HD 2
NB_HA 8
fsp3 0.47
Lipinski(0=no;1=yes) 0

FDA
NDA 211723 (label) INN (TAZEMETOSTAT HYDROBROMIDE) TAZVERIK (EPIZYME INC) APPROVAL= AP YEAR= 2020 NEWMOLECULARENTITY
NDA 213400 (label) INN (TAZEMETOSTAT HYDROBROMIDE) TAZVERIK (EPIZYME INC) APPROVAL= AP YEAR= 2020 NEWAPPLICATION